First Quadrant’s Ligand Pharmaceuticals LGND Stock Holding History

First Quadrant’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,821	Closed	-$1.33M	–	347
2021 Q4	$1.33M	Hold	13,821	–	–	0.14%	136
2021 Q3	$1.2M	Hold	13,821	–	–	0.14%	140
2021 Q2	$1.13M	Hold	13,821	–	–	0.13%	149
2021 Q1	$1.31M	Hold	13,821	–	–	0.14%	142
2020 Q4	$857K	Buy	13,821 +6,617	+92%	+$377K	0.09%	176
2020 Q3	$428K	Sell	7,204 -1,912	-21%	-$130K	0.05%	237
2020 Q2	$636K	Buy	+9,116	New	+$578K	0.09%	219
2019 Q2	–	Sell	-3,238	Closed	-$254K	–	733
2019 Q1	$254K	Sell	3,238 -4,841	-60%	-$367K	0.02%	460
2018 Q4	$684K	Sell	8,079 -1,693	-17%	-$180K	0.06%	300
2018 Q3	$1.67M	Buy	9,772 +6,503	+199%	+$980K	0.04%	331
2018 Q2	$422K	Buy	+3,269	New	+$365K	0.01%	513
2014 Q4	–	Sell	-23,724	Closed	-$695K	–	795
2014 Q3	$695K	Hold	23,724	–	–	0.02%	414
2014 Q2	$922K	Buy	23,724 +16,190	+215%	+$657K	0.02%	397
2014 Q1	$316K	Buy	7,534 +1,603	+27%	+$66.8K	0.01%	487
2013 Q4	$195K	Buy	+5,931	New	+$193K	﹤0.01%	560

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

First Quadrant's LGND Position: Q1 2022 in Review

First Quadrant sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 13,821 shares — an estimated $1.33M sold.

First Quadrant first reported a position in LGND in Q4 2013 and held it in 15 quarters. The position peaked at $1.67M in Q3 2018. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

First Quadrant reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 13,821 Ligand Pharmaceuticals shares in Q1 2022, an estimated $1.33M.
First Quadrant first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 15 quarters.
First Quadrant's Ligand Pharmaceuticals position peaked at $1.67M in Q3 2018.
208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.